NT-A9, a new triazole, exhibits potent antifungal activity against Candida and Cryptococcus species through potent ergosterol biosynthesis inhibition

Antimicrobial Agents and Chemotherapy · Published 2026-08-05 · DOI 10.1128/aac.00768-26

Free full text

Authors (8)

Shuo Zhu, Tingjunhong Ni, Lu Gao, Wanqian Li, Dazhi Zhang, Wenjuan Wu, Yuanying Jiang, Hui Lu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Zhu, S., Ni, T., Gao, L., et al. (2026). NT-A9, a new triazole, exhibits potent antifungal activity against Candida and Cryptococcus species through potent ergosterol biosynthesis inhibition. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00768-26

Related articles

• Candida auris: Epidemiology and Antifungal Strategy · Annual Review of Medicine · 2024 · Cites or is cited by this article
• PER-14, a β-lactamase variant with reduced sensitivity to avibactam and relebactam · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• An Achilles' heel for methicillin-resistant Staphylococcus aureus ? Re-evaluating β-lactam susceptibility of MRSA · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• A community-based One Health approach to the pandemic dynamics of Escherichia coli ST131 · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Development of domain-specific probes of Plasmodium falciparum heat shock protein 70-1 · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Primaquine-derived 5,6-orthoquinone concentrations in urine associated with CYP2D6 genotype-predicted phenotype and blood methemoglobin levels · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Selective digestive decontamination and antimicrobial resistance: defining thresholds before global implementation · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• Recalculation of inhibitor concentration fold-changes for CMY-219: comments on a recent article about CMY-219 conferring resistance to ceftazidime-avibactam · Antimicrobial Agents and Chemotherapy · 2026 · Same journal
• NagX, a periplasmic β- N -acetylglucosaminidase, contributes to NagZ-independent β-lactamase expression in Stenotrophomonas maltophilia · Antimicrobial Agents and Chemotherapy · 2026 · Same journal